• The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009. 
• In March 2019, the FDA approved Spravato-non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, in conjunction with an oral antidepressant, for the TRD treatment in adults. It is the first-ever approved NMDA therapy for TRD. 
• Dominant players such as Eli Lilly and Company, Johnson& Johnson,  Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals, and others involved in developing targeted TRD therapeutics.
• The Treatment-Resistant Depression market is expected to show positive growth, mainly attributed to an increased number of TRD cases and the expected launch of therapies such as AXS-05, ALKS-5461, Cariprazine, Seltorexant, Pimavanserin, MIJ821, Esketamine DPI, Psilocybin, REL-1017, and others.
• With a novel mechanism of action, these therapies may change the Treatment-Resistant Depression treatment regimen by 2030.

According to DelveInsight's analysts, the total diagnosed Treatment-Resistant Depression prevalent population in 7MM was estimated to be 4,464,781 cases in 2017. The females appear to have a predisposition to Treatment-Resistant Depression, which is why a higher percentage of prevalence was observed in females than males in the United States.

The TRD Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

Get a sample copy of this report: Treatment-Resistant Depression Market Landscape

Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment.

Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant. 

Despite an increasing variety of choices for the treatment of TRD, this condition continues to be universally undefined and represents an area of unmet medical need. There are only a few known approved TRD pharmacological agents. So, various biotechnological companies are working towards the development of targeted TRD therapeutics. 

• ALKS 5461: Alkermes
• Cariprazine: Allergan/Gedeon Richter
• Pimavanserin: ACADIA Pharmaceuticals
• AXS-05: Axsome Therapeutics
• Seltorexant: Johnson and Johnson/Minerva Neurosciences
• Esketamine DPI: Celon Pharma
• REL-1017: Relmada Therapeutics
• AV-101: VistaGen Therapeutics
• MIJ821: Novartis
• Psilocybin (COMP360): COMPASS Pathways

Final comments on Treatment-Resistant Depression Market Growth 

• Research and Development - Increase in the understanding of pathophysiology and the development of novel therapeutic compounds have emerged.
• Development of Pioneering Therapies - Various drugs are in the trial that can help in the growth of the TRD market in the future. Next-generation SSRI antidepressants are being developed with the promise of better tolerability. Demand for the new antidepressant agents leads to an increase in research activities, and researchers are focusing on the various targets such as NMDA and others.
• Retainment of Current Management Strategies and Refined Clinical Trial Design 

• Economic Burden - The burden of depression is increasing despite advancements in treatments. Several factors contribute to the economic burden, including the prevalence, rate, degree of impairment, and lesser remission.
• Variable Treatment Response - The disease is itself treatment-resistant which encourages increasingly risky treatment interventions that are likely to affect patients negatively Treatment options are limited and also with increased toxicity with higher dosages and combination regimens.
• Commercial Challenges - Stringent policies for regulatory approvals can be a threat to the TRD market. Gaining market access and reimbursement further complicates it.

Scope of the Treatment-Resistant Depression Market Insight Report 

• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
• Treatment-Resistant Depression Markets Segmentation: By Geographies and By Treatment-Resistant Depression Therapies (Historical and Forecasted, Current and Upcoming) 
• Dominant Market Companies investigating its candidates for Treatment-Resistant Depression: Eli Lilly and Company, Johnson& Johnson,  Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies.
• Case Studies
• KOL's Views
• Analyst's View

Browse full report with detailed TOC with charts, figures, tables @ Treatment-Resistant Depression Market Size Report 

• Treatment-resistant depression Epidemiology Forecast Analysis 

• Treatment-Resistant Depression Pipeline Analysis 

• Bipolar Disorder (Manic Depression) Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

• VCF Treatment Devices Market Insights, Competitive Landscape, and Market Forecast Analysis 

Shruti Thakur 
[email protected] 
+1(919)321-6187 
www.delveinsight.com